A precision therapy against cancers driven by KIT/PDGFRA mutations-Reference-Cited by-同舟云学术

A precision therapy against cancers driven by KIT/PDGFRA mutations

Published:2017-11 Issue:414 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Evans Erica K.¹^ORCID,Gardino Alexandra K.¹,Kim Joseph L.¹^ORCID,Hodous Brian L.¹^ORCID,Shutes Adam¹,Davis Alison¹^ORCID,Zhu Xing Julia¹^ORCID,Schmidt-Kittler Oleg¹^ORCID,Wilson Doug¹,Wilson Kevin¹,DiPietro Lucian¹,Zhang Yulian¹,Brooijmans Natasja¹^ORCID,LaBranche Timothy P.¹^ORCID,Wozniak Agnieszka²,Gebreyohannes Yemarshet K.²,Schöffski Patrick²^ORCID,Heinrich Michael C.³^ORCID,DeAngelo Daniel J.⁴,Miller Stephen¹,Wolf Beni¹,Kohl Nancy¹^ORCID,Guzi Timothy¹^ORCID,Lydon Nicholas¹^ORCID,Boral Andy¹^ORCID,Lengauer Christoph¹^ORCID

Affiliation:

1. Blueprint Medicines, Cambridge, MA 02139, USA.

2. Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Belgium 3000.

3. VA Health Care System and Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.

4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Abstract

BLU-285 is a selective and potent mutant KIT and PDGFRA inhibitor active in both preclinical and clinical settings.

Funder

U.S. Department of Veterans Affairs

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

2. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

3. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

5. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Advanced Systemic Mastocytosis: Clinical Challenges;Journal of Blood Medicine;2024-09

2. Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research;Global Medical Genetics;2024-08-22

3. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

4. Unraveling the Rare Entity of KIT D816V-Negative Systemic Mastocytosis;Journal of Hematology;2024-06

5. Vascular architecture regulates mesenchymal stromal cell heterogeneity via P53-PDGF signaling in the mouse incisor;Cell Stem Cell;2024-06